---
title: 'Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary
  arterial hypertension: long-term follow-up data from EDITA study'
date: '2024-07-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39026360/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240719181339&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: In SSc patients with early PVD, the development of PAH and/or
  deterioration was less frequent among patients receiving ambrisentan, indicating
  that early treatment and close follow-up could be beneficial in this high-risk group.
  Future trials in this field are needed to confirm these ...'
disable_comments: true
---
CONCLUSION: In SSc patients with early PVD, the development of PAH and/or deterioration was less frequent among patients receiving ambrisentan, indicating that early treatment and close follow-up could be beneficial in this high-risk group. Future trials in this field are needed to confirm these ...